Condition: Soft-tissue Sarcomas · Sponsor: Institut Bergonié
This is a prospective observational biomarker study including patients with non-metastatic, soft-tissue sarcomas (STS) for whom neoadjuvant chemotherapy is considered as the best option by the multidisciplinary sarcoma team of one of the participating centers.
This description comes directly from the study's public registry record.
Antoine ITALIANO, MD,PhD · a.italiano@bordeaux.unicancer.fr
Simone MATHOULIN-PELISSIER, MD,PhD · s.mathoulin@bordeaux.unicancer.fr
Always discuss trial participation with your own doctor first.
| Institut Bergonié | Bordeaux, France | Recruiting |
| Centre Georges François Leclerc | Dijon, France | Recruiting |
| Centre Oscar Lambret | Lille, France | Not Yet Recruiting |
| Centre Léon Bérard | Lyon, France | Recruiting |
| Institut Paoli Calmettes | Marseille, France | Recruiting |
| AP-HM _ Hôpital de la Timone | Marseille, France | Recruiting |
| Institut de Cancérologie de l'Ouest | Nantes, France | Recruiting |
| Institut Curie | Paris, France | Not Yet Recruiting |
| Institut Claudius Regaud - IUCT-0 | Toulouse, France | Recruiting |
| Institut Gustave Roussy | Villejuif, France | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02789384